Drugs Made In America merger agreement sets $2.85 billion closing valuation including APQC acquisition
DMAA•Drugs Made In America Acquisition Corp. and PAGC amended their merger agreement on Oct. 13, setting a $2.85 billion closing valuation including the APQC acquisition. If APQC is not completed by Nov. 1, PAGC’s standalone closing valuation will be $1.71 billion.
1. Amended merger terms
Drugs Made In America Acquisition Corp. and PAGC entered an amendment to their merger agreement on Oct. 13. The agreement provides for a $2.85 billion closing valuation including the APQC acquisition, or a $1.71 billion standalone closing valuation for PAGC if the APQC acquisition is not completed by Nov. 1.
